Αbstract
The therapeutic management of human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) is constantly evolving and improving. Newer drugs with greater efficacy and fewer side effects continue to broaden therapeutic options, offering better pharmacokinetic profiles, higher genetic barriers and easier dosing regimens. Some companies have already begun marketing co-formulated drugs, offering single-tablet, once-a-day treatments and more are sure to follow.
Successful treatments have led to significantly prolonged survival rates. Such successes, however, have brought complications: when patients survive longer, comorbidities begin to emerge, inducing premature ageing and frailty. Treating HIV/AIDS becomes more complicated as a result, requiring the cooperation of many specialists.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Further Reading
Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785–92.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–56.
Autran B. Effects of antiretroviral therapy on immune reconstitution. Antivir Ther. 1999;4(Suppl 3):3–6.
Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–55.
Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423–30.
Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51–8.
Catanzaro LM, Slish JC, DiCenzo R, Morse GD. Drug interactions with antiretrovirals. Curr HIV/AIDS Rep. 2004;1(2):89–96.
Cohen MS, Chen YQ, McAuley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–9.
Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2020a. www.aidsinfo.nih.gov/guidelines.
Department of Health and Human Services. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. January 2020b. www.aidsinfo.nih.gov/guidelines.
DHHS, 14th report on carcinogens, November 3, 2016, https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html
ECDC: HIV/AIDS surveillance in Europe 2019. https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance-europe-2019-2018-data.
European AIDS Clinical Society (EACS). Guidelines, version 10.0, November 2019 Version 7.0. 2013.
European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. ECDC; 2011. www.ecd.europa.eu
Eyawo O, Franco-Villalobos C, Hull MW, Nohpal A, Samji H, Sereda P, Comparative Outcomes And Service Utilization Trends (COAST) Study, et al. Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infect Dis. 2017;17(1):174.
Hart GJ, Elford J. Sexual risk behaviour of men who have sex with men: emerging patterns and new challenges. Curr Opin Infect Dis. 2010;23(1):39–44.
Hayes R, Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P, et al. Estimating the ‘PrEP gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Euro Surveill. 2019;24(41). https://doi.org/10.2807/1560-7917.
Jiang J, Yang X, Ye L, Zhou B, Ning C, Huang J. Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e87674.
Manabe YC, Campbell JD, Sydnor E, Morre RD. Immune reconstitution inflammatory syndrome. Risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46(4):456–62.
Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study. Antivir Ther. 2010;15(3):413–23.
Messiaen P, Wensing AMJ, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8(1):e52562.
Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4:9.
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393:2428–38.
Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(5):676–86.
US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 UPDATE. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200(10):1503–8.
Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. ΗΙV Med. 2013;14(4):195–207.
Werner RN, Gaskins M, Nast A, Dressler C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection—a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS One. 2018;13(12):e0208107.
Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Paparizos, V., Kourkounti, S. (2023). HIV Infection and AIDS: The Present Status of Antiretroviral Therapy. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D'Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Cham. https://doi.org/10.1007/978-3-031-15130-9_41
Download citation
DOI: https://doi.org/10.1007/978-3-031-15130-9_41
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-15129-3
Online ISBN: 978-3-031-15130-9
eBook Packages: MedicineMedicine (R0)